Metraipolis › archive › dc_87d07fea2732

Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System — Europe PMC PMID:40963942

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40963942
DOI
10.3389/fneur.2025.1625612
License (as archived)
solo-consultazione
Archived
2026-11-10T04:22:31.848Z
SHA-256 of the archived text
4108af97ae1eb8fb28a1a5b3d83d1a14198efca68c86145b70338949dcf1dcbd
Stable URL of this page
https://metraipolis.com/documento/dc_87d07fea2732

How to cite

Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System — Europe PMC PMID:40963942 — Europe PMC (en), https://europepmc.org/article/MED/40963942 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_87d07fea2732 (Metraipolis archive dc_87d07fea2732, sha256 4108af97ae1eb8fb28a1a5b3d83d1a14198efca68c86145b70338949dcf1dcbd)
BibTeX
@misc{dc87d07fea2732,
  title = {Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System — Europe PMC PMID:40963942},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40963942},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_87d07fea2732; sha256 4108af97ae1eb8fb28a1a5b3d83d1a14198efca68c86145b70338949dcf1dcbd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40963942. Agents can read the archived copy with the MCP tool read_document.